Masters Thesis Defense
description
Transcript of Masters Thesis Defense
Microarray Analysis of the Effects of Rosiglitazoneon Gene Expression in Neonatal Rat Ventricular
Myocytes
Elliot KleimanSan Diego State University
Masters Thesis Defense in Computational ScienceSeptember 17, 2009
Outline
1 IntroductionIllumina BeadArray technology
2 Materials & MethodsData Analysis
3 ResultsDifferential expressionKEGG pathway analysisGene ontology analysis
4 Discussion
5 Acknowledgements
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 2 / 41
Outline
1 IntroductionIllumina BeadArray technology
2 Materials & MethodsData Analysis
3 ResultsDifferential expressionKEGG pathway analysisGene ontology analysis
4 Discussion
5 Acknowledgements
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 2 / 41
Outline
1 IntroductionIllumina BeadArray technology
2 Materials & MethodsData Analysis
3 ResultsDifferential expressionKEGG pathway analysisGene ontology analysis
4 Discussion
5 Acknowledgements
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 2 / 41
Outline
1 IntroductionIllumina BeadArray technology
2 Materials & MethodsData Analysis
3 ResultsDifferential expressionKEGG pathway analysisGene ontology analysis
4 Discussion
5 Acknowledgements
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 2 / 41
Outline
1 IntroductionIllumina BeadArray technology
2 Materials & MethodsData Analysis
3 ResultsDifferential expressionKEGG pathway analysisGene ontology analysis
4 Discussion
5 Acknowledgements
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 2 / 41
Diabetes
What is it?How many people are affected?Cardiovascular complications
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 3 / 41
Diabetes
What is it?How many people are affected?Cardiovascular complications
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 3 / 41
Diabetes
What is it?How many people are affected?Cardiovascular complications
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 3 / 41
Rosiglitazone
Prescription drug which lowers blood sugar levelsAvandia®(1999, GlaxoSmithKline), U.S. patent 2012Controversial drug
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 4 / 41
Rosiglitazone
Prescription drug which lowers blood sugar levelsAvandia®(1999, GlaxoSmithKline), U.S. patent 2012Controversial drug
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 4 / 41
Rosiglitazone
Prescription drug which lowers blood sugar levelsAvandia®(1999, GlaxoSmithKline), U.S. patent 2012Controversial drug
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 4 / 41
Previous work
Shah et al. 2002 (M.Sci Biology, SDSU) found that Rosiglitazone:Improves cardiac contractility by enhancing cytosolic calciumremovalIncreases SERCA2 mRNA, protein, and promoter activityIncreases NFκB promoter and IL-6 protein secretion
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 5 / 41
Previous work
Shah et al. 2002 (M.Sci Biology, SDSU) found that Rosiglitazone:Improves cardiac contractility by enhancing cytosolic calciumremovalIncreases SERCA2 mRNA, protein, and promoter activityIncreases NFκB promoter and IL-6 protein secretion
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 5 / 41
Previous work
Shah et al. 2002 (M.Sci Biology, SDSU) found that Rosiglitazone:Improves cardiac contractility by enhancing cytosolic calciumremovalIncreases SERCA2 mRNA, protein, and promoter activityIncreases NFκB promoter and IL-6 protein secretion
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 5 / 41
Previous work
Shah et al. 2002 (M.Sci Biology, SDSU) found that Rosiglitazone:Improves cardiac contractility by enhancing cytosolic calciumremovalIncreases SERCA2 mRNA, protein, and promoter activityIncreases NFκB promoter and IL-6 protein secretion
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 5 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Current thesis work
Are there other genes affected by rosiglitazone in addition toSERCA2?Can we:
identify these genes?determine their functional relationships?classify these genes as early or late responders over time?
How to implement these objectives?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 6 / 41
Gene expression primer
DNA
RNA
PROTEIN
Replication
(RNA synthesis)
(Protein synthesis)
Transcription
Translation
Genes
Phenotype
GeneExpression
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 7 / 41
Experimental approach
DNA microarrays, useful why?because one can measure the gene expression levels of thousandsof genes simultaneouslybecause measuring the levels of mRNA is easier than measuringlevels of proteinsbecause mRNA is a good surrogate marker for protein (or is it?)because when you don’t have a hypothesis, microarrays can helpyou find one
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 8 / 41
Experimental approach
DNA microarrays, useful why?because one can measure the gene expression levels of thousandsof genes simultaneouslybecause measuring the levels of mRNA is easier than measuringlevels of proteinsbecause mRNA is a good surrogate marker for protein (or is it?)because when you don’t have a hypothesis, microarrays can helpyou find one
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 8 / 41
Experimental approach
DNA microarrays, useful why?because one can measure the gene expression levels of thousandsof genes simultaneouslybecause measuring the levels of mRNA is easier than measuringlevels of proteinsbecause mRNA is a good surrogate marker for protein (or is it?)because when you don’t have a hypothesis, microarrays can helpyou find one
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 8 / 41
Experimental approach
DNA microarrays, useful why?because one can measure the gene expression levels of thousandsof genes simultaneouslybecause measuring the levels of mRNA is easier than measuringlevels of proteinsbecause mRNA is a good surrogate marker for protein (or is it?)because when you don’t have a hypothesis, microarrays can helpyou find one
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 8 / 41
Experimental approach
DNA microarrays, useful why?because one can measure the gene expression levels of thousandsof genes simultaneouslybecause measuring the levels of mRNA is easier than measuringlevels of proteinsbecause mRNA is a good surrogate marker for protein (or is it?)because when you don’t have a hypothesis, microarrays can helpyou find one
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 8 / 41
Illumina BeadArray technology
Source: Illumina.com, Mark Dunning
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 9 / 41
Bead design
Address Probe
29b 50b
LabelledcRNA
BEAD DESIGN
Gene-speci�c probes are concatenatedwith a short "address sequence."
Source: Illumina.com
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 10 / 41
Materials & Methods
Drug = rosiglitazoneControl = dimethylsulfoxide (DMSO)Two samples of ≈100 newborn (neonatal) rats
isolated and cultured neonatal rat ventricular myocytes (NRVMs)
48 arrays or 4 Illumina RatRef-12 Expression BeadChips
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 11 / 41
Study Design
Table: 12×2 Factorial Design
Timea
(hour)
0b ½ 1 2 4 6 8 12 18 24 36 48
Drug DMSO -c +d + + + + + + + + + +Rosiglitazone - + + + + + + + + + + +
DMSO, dimethylsulfoxide.a Exposure time to drug treatment.b Untreated RNA.c No drug administered.d Drug administered.
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 12 / 41
Array hybridization layout
Sample 1
1677718214
06/21/07
R 0.5hrD 48hr
D 36hrD 24hr
D 18hr
D 8hr
D 4hr
D 1hr
D12 hr
D 6hr
D 2hr
D 0.5hr
1677718210
06/21/07
UU
R 48hrR 36hr
R 24hr
R 12hr
R 6hr
R 2hr
R 18hr
R 8hr
R 4hr
R 1hr
AB
CD
E
G
I
K
F
H
J
L
A
C
E
G
I
KL
J
H
F
D
B
Sample 2
1677718217
07/10/07
R 0.5hrD 48hr
D 36hrD 24hr
D 18hr
D 8hr
D 4hr
D 1hr
D12 hr
D 6hr
D 2hr
D 0.5hr
1677718209
07/10/07
UU
R 48hrR 36hr
R 24hr
R 12hr
R 6hr
R 2hr
R 18hr
R 8hr
R 4hr
R 1hr
AB
CD
E
G
I
K
F
H
J
L
A
C
E
G
I
KL
J
H
F
D
B
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 13 / 41
Microarray Experiment Steps
1 Biological Question2 Design of Experiment3 Sample Preparation (mRNA extraction)4 Array Processing5 Image Analysis6 Pre-processing of Data (Normalization, Filter)7 Data Analysis8 Statistical Inference
Source: Sonia Jain, Ph.D (Microarray Technologies, 2006)
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 14 / 41
Data Analysis
Data analysis goal: to find an association between treatmentcondition and gene expressionCommon gene selection strategies:
Fold changeParametric test: two sample t-testNon-parametric tests: rank sum, signed-rank testsANOVAPermutation or bootstrap resampling. . . zillions of others!
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 15 / 41
Data Analysis
Data analysis goal: to find an association between treatmentcondition and gene expressionCommon gene selection strategies:
Fold changeParametric test: two sample t-testNon-parametric tests: rank sum, signed-rank testsANOVAPermutation or bootstrap resampling. . . zillions of others!
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 15 / 41
Data Analysis
Data analysis goal: to find an association between treatmentcondition and gene expressionCommon gene selection strategies:
Fold changeParametric test: two sample t-testNon-parametric tests: rank sum, signed-rank testsANOVAPermutation or bootstrap resampling. . . zillions of others!
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 15 / 41
Data Analysis
Data analysis goal: to find an association between treatmentcondition and gene expressionCommon gene selection strategies:
Fold changeParametric test: two sample t-testNon-parametric tests: rank sum, signed-rank testsANOVAPermutation or bootstrap resampling. . . zillions of others!
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 15 / 41
Linear models of microarrays (LIMMA)
Linear Model
log(ygi) = µg + βgRxRi + βgDxDi + βgR:DxRi xDi + εgi (1)
Idea: use a linear model to parameterize the effects of drug andtime from our factorial designed experiment
Source: Smyth, Limma (2004)
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 16 / 41
Moderated, bayesian t-test
Moderated t-statistic
s2g =
d0s20 − dgs2
g
d0 + dg
t∗g =βg
sgug
(2)
Std.Err used in test-statistic is a weighted average of s20 + s2
g
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 17 / 41
Significant contrasts of interest
Table: Numbers of genes regulated during significant exposure times torosiglitazone vs. DMSO in NRVMs
Significant exposure times for rosiglitazone vs. DMSO(hour)
2 4 6 8 12 18 24 36 48
No. genesregulated
-1a 0 0 0 0 0 0 2 8 90b 22516 22513 22514 22513 22506 22506 22498 22491 224911c 1 4 3 4 11 11 17 18 17
a Numbers of genes down-regulated.b Numbers of genes unchanged.c Numbers of genes up-regulated.
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 18 / 41
Differentially expressed genes
1-10Abca1
Acaa2
Acadv1
Acot7
Adfp
Aldh3a2
Angptl4
Aqp7
Arhgdib
Ccl12
11-20Cidea
Cyp1b1
Dapp1
Decr1
Dpt
Ech1
Entpd2
Etfdh
Grip2
Gusb
21-30Hmgcs2
Impa2
Kel
LOC501283
LOC501396
LOC691522
Lpcat3
Olr472
Psmb9
Ptprr
31-37RGD1309930
RGD1310039
RT1-CE15
Rassf6
Retsat
Tap1
Vipr2
Angptl4 and Adfp most consistently expressed (up-regulated) over time course!
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 19 / 41
Time course expression profile 4 h
0.0
0.5
1.0
1.5
2.0
2.5
Time ((hour))
Log 2
fold
cha
nge
0 4 8 12 16 20 24 28 32 36 40 44 48
●
●
Gene
Angptl4Cyp1b1Olr472Adfp
●
●
●
●
●
●●
●
●
● ●
●
●
●●
●
●
● ●●
●● ●
●
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 20 / 41
Time course expression profile 36 h
−0.
50.
00.
51.
01.
52.
02.
53.
0
Time ((hour))
Log 2
fold
cha
nge
0 4 8 12 16 20 24 28 32 36 40 44 48
●
●
●
●
●
●
●
●
Gene
Angptl4Ech1Abca1Hmgcs2Acaa2Lpcat3Impa2Decr1AdfpAcot7EtfdhAcadvlRetsatCideaGrip2Vipr2Aqp7Aldh3a2KelDapp1LOC501396LOC691522PtprrEntpd2GusbDpt
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●●
●●
● ●
●●
●
● ●
●
●●●●
● ● ●
●
●
●
● ●
●●
●
●
● ●● ● ●
●●
●
●
●
●
●
●
●
●● ●
●
●
●
●●●
● ● ● ●●
●
●
●
●
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 21 / 41
Hcl heatmap 4 h
0.5
hour
1 ho
ur
2 ho
ur
4 ho
ur
6 ho
ur
8 ho
ur
12 h
our
18 h
our
24 h
our
36 h
our
48 h
our
Cyp1b1
Olr472
Adfp
Angptl4
−2.0 −1.5 −1.0 −0.5 0.0 0.5 1.0
dummy.x
1
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 22 / 41
Hcl heatmap 36 h
0.5
hour
1 ho
ur
2 ho
ur
4 ho
ur
6 ho
ur
8 ho
ur
12 h
our
18 h
our
24 h
our
36 h
our
48 h
our
Angptl4Entpd2GusbDptLOC691522LOC501396PtprrDapp1KelEch1Acaa2Abca1Hmgcs2Vipr2CideaAqp7Aldh3a2Grip2Impa2AdfpAcot7Decr1Lpcat3RetsatAcadvlLpcat3Etfdh
−2 −1 0 1 2
dummy.x
1
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 23 / 41
What is a biological pathway?
Biological process: The set of all molecules required to perform abiological function
Biological pathway: The set of all molecular interactions that belong toa biological process
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 24 / 41
Overrepresented KEGG pathways
PPAR signalingFatty acid metabolismSynthesis and degradation of ketone bodiesValine, leucine, and isoleucine degradationButanoate metabolismBile acid metabolismATP binding cassette transporters, general
biol. pathway theme: fatty acid and lipid metabolism and mitochondrial energy transfer
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 25 / 41
Gene ontology, what is it?
structured vocabulary for describing genes and gene productsmolecular function (what it does)biological process (how it contributes)cellular component (where it does it)
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 28 / 41
Hypergeometric testing
test of association between two categories of interest (equivalentto Fisher’s Exact test)used to assess the over-representation of GO termshow many genes in the universe(array) are annotated at a giventerm?how many of those are also in the set of interesting genes?
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 29 / 41
Hypergeometric testing case example
Universe = 1000 genes, 400 are DE, GO term has 40 annotationsWhat is the Prob that 10 of the 40 genes in GO term are also in the setof DE?
DE DE Total
In GO term 10 30 40On Array 390 570 960Total 400 600 1000
Falcon, GOstats, 2007
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 30 / 41
Hypergeometric random variable
e.g., sampling balls from an urn model without replacement each trialis dependent on the previous one
Hypergeometric random variable
P(y) =
(ky
)(N−kn−y
)(Nn
)where N = population size k = number of population successes n =sample size y = number of sample successes
from prev slide we would have,
P(10) =
(40010
)(60030
)(100040
) = 0.99
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 31 / 41
Overrepresented GO terms
Biological processprimary metabolicprocess
lipid metabolic process
cellular lipid metabolicprocess
oxidation reduction
response to drug
Cellular componentlipid particle
mitochondrion
mitochondral membrane
mitochondral innermembrane
nuclearenvelope-endoplasmicreticulum network
Molecular functioncatalytic activity
electron carrier activity
transferase activity
transferring acyl groups
acyltransferase activity
oxidoreductase activity
gene ontology theme: energetic and metabolism activities
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 32 / 41
Induced GOBP 8 h
1525
1568
1666
1944 6066
6082
6461
6629
6631
6694
6695
6720
6810
6869
6915
6950
7154
7165
7275
7584
8150
8152
8202
8203
8219
8299
8610
9058
9605
9653
9719
9725
9887
9987
99910033 0876
2501 4070
5908
5909
6043
6125
6126
6265
9216
9222
9752
991526070154 1667
2501 2502
2787
30362221
2493
2981
3066
3067
3069
3086 34343933
4237
4238
4249 42556950
6951
8513
8514
8519
85238646
8731
8856
8869
0789
0790 0793 0794
0896
1004
1005
1093
1179
1234
1259
1260
1336
1346 0191
0192
5003
5007
5009
0271
●
●
●
p < 0.01
p >= 0.01
None from gene list
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 33 / 41
Angptl4 & Adfp
Angptl4, Angiopoietin-like protein 4up-regulated 3 to 7 fold
potent inhibitor of LPL
plays key role in modulating cardiacsubstrate metabolism
decreases TG delivery to heart for FA βoxidation
Adfp, Adipose differentiation proteinup-regulated 1.5 to 1.7 fold
plays a key role in formation of lipiddroplets
lipid droplet associated protein
adipocyte differentiation
responsible for increase in subcutaneoustissue mass observed in rosiglitazone
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 34 / 41
Lipid & energy metabolism in cardiomyocytes
FFA
Fatty Acyl-CoA
TG synthesis
Lipoprotein secretion
TG
lipolysis
Energy uncoupling
ATP
FATP CD36
LACS
MitochondriaIntermembrane
space
AcylcarnitineCarnitine
Coenzyme A
Acyl-CoA + Acetyl-CoA
Acyl-CoA
TCA cycle
Enoyl-CoA
3-OH-acyl-CoA
3-ketoacyl-CoA
CPT-I
FAD +FADH
NAD +
NAD+H +
H2O
CoA-SH
CO 2
UCP2,UCP3
CPT-II CACT
Outer membrane
Inner membrane
E lec tron re
s pirato
ry c
hain
LCAD
Enoyl-CoAhydratase
HAD
Thiolase
VLDLTG
ChylomicronsTG
AlbuminFFA
LDLTG
Yang & Li 2007Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 35 / 41
Actions of PPARγ in FA trapping
Semple, 2006
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 36 / 41
Molecular mechanisms of TZDs
PPARg
PPARg PPARg
PPARg
PPARg RXR
Transactivation Transrepression
Coactivator binding site
Ligand binding siteCoactivator fragment
X X X
Ligands Ligands
Coactivator
PPRE PPRE
PPAR target genes
p65 p50 Fos Jun STAT1 STAT3
NF-kB-RE TRE ISGF-RE
noitavitca dnagiLnoitavitca dnagiL
Cofactor recruitment
DZTDZT
Hannele Yki-Jarvinen, 2004Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 37 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Limitations
DrugNo PCR validationNo assay for PPARγ levelstechnician-level variationLimitations of the array technologySample size of 2No db/db disease model
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 38 / 41
Acknowledgements
SDSUPaul Paolini
Jose Castillo
Peter Salamon
James Otto
Frank Gonzales
Lynelle Garnica
KirubelGebresenbet
Magda Nemeth
David Torres
UC San DiegoGary Hardiman
Roman Sasik
Charles Berry
Jennifer Lapira
NorthwesternUniversityDenise Scholtens
Pan Du
Simon Lin
UC RiversideThomas Girke
EvriSeth Falcon
Linux administrationGreg Chandler
Illumina, Inc.Andrew Carmen
EMD Biosciences
Huda Shubeita
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 39 / 41
Non-normalized array data
●
●●
●
●●●●
●
●
●
●
●
●
●●●●
●
●●●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●●
●
●
●●
●●
●
●
●●●●
●
●
●
●
●
●
●
●●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●●●●●
●
●●●●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●●●●●
●
●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●●●
●
●
●
●
●
●
●●●●
●
●●●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●●
●●
●●
●●
●●●
●
●
●
●
●
●
●●●●
●
●●●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●●
●●
●
●
●●●●
●
●
●
●
●
●
●●●●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●●
●
●
●●
●●●
●
●
●
●
●
●
●●●●
●
●●●●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●●
●●
●
●
●●
●●●
●
●
●
●
●
●
●●●●
●
●●●●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●●
●
●●●●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●●
●
●
●
●
●
●
●●●●
●
●●●
●●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●●
●●●
●
●
●
●
●
●
●●●
●
●●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●●
●
●●●●●●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●●●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●●●
●●
●
●●
●
●
●
●
●●●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●●●●●●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●●
●●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●●●
●
●●
●●
●
●
●●●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●●●●●
●
●
●
●●
●
●
●
●●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●●
●
●
●
●●
●
●●
●●
●●
●
●●●●●
●
●
●
●
●
●
●●
●
●●●●●●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●●●●●●
●
●
●
●●
●
●
●
●●●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●●●●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●
●●●●●●●
●
●
●
●●
●
●
●
●●
●
●
●●
●●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●●●●●
●
●
●
●●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●●
●●●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●●●●●●
●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●●●●●●●
●
●
●
●
●
●
●
●●●●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●●●●●
●
●●
●●
●
●
●
●●●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●●●●●
●
●
●
●
●
●
●
●●●●●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●●
●●
●●
●●●●●●●
●
●
●
●●
●
●
●
●●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●●●●
●
●
●
●●
●
●
●●●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●●●●●●●
●
●
●
●
●
●
●
●●●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●●●●●●●
●
●
●
●●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●●●●●
●
●
●
●●
●
●
●
●●●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●●
●
●●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●●
●●●
●
●
●
●●
●
●
●
●●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●●●●●●●●
●
●
●
●●
●
●
●
●●●●
●
●●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●●
●●
●
●●●●
●
●
●
●
●
●
●●●●●
●
●●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●●●●
●●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●●
●
●●
●
●●●●
●
●
●
●●
●
●
●●●
●
●●●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●●●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●●●●
●
●●●●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●●●
●
●●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●
●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●●●
●
●
●
●●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●●●
●
●
●
●
●
●
●●
●
●●●●●
●
●●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
un2−
1un
2−2
R48
−2
R36
−2
R24
−2
R18
−2
R12
−2
R8−
2R
6−2
R4−
2R
2−2
R1−
2un
1−1
un1−
2R
48−
1R
36−
1R
24−
1R
18−
1R
12−
1R
8−1
R6−
1R
4−1
R2−
1R
1−1
R.5
−1
D48
−1
D36
−1
D24
−1
D18
−1
D12
−1
D8−
1D
6−1
D4−
1D
2−1
D1−
1D
.5−
1R
.5−
2D
48−
2D
36−
2D
24−
2D
18−
2D
12−
2D
8−2
D6−
2D
4−2
D2−
2D
1−2
D.5
−2
6
8
10
12
14
log2
inte
nsity
Array (Treatment)Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 40 / 41
Normalized array data
●
●
●
●
●
●
●●
●
●●●●●
●●●
●
●
●
●●
●
●
●
●●
●●
●
●●●
●
●●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●●●
●
●
●●
●
●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●●●●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●●
●
●
●
●●
●
●
●
●●●●
●
●●●
●
●●
●
●
●
●●●●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●●●
●
●
●
●●
●
●
●
●●●
●
●
●●
●●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●
●●
●
●
●
●●
●
●●●
●●
●
●●●
●
●●●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●●●
●
●
●
●●
●
●
●●
●●
●
●●
●
●●
●
●●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●●●
●●●
●
●
●
●●
●
●
●●●●
●
●●●
●●
●
●●●
●
●●●●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●●●
●
●
●
●●
●
●
●
●●●●
●
●
●●
●●
●
●●●
●
●●●●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●
●
●
●
●●
●
●
●●●
●
●●●
●●
●●
●
●
●
●
●●
●
●
●●
●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●●●
●
●
●
●●●
●
●
●
●●●●
●
●●
●
●●
●
●
●●
●
●●●
●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●●●
●
●
●
●●
●
●
●
●●●●
●
●●
●
●
●
●
●
●●
●
●●●
●
●
●●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●●●
●
●●
●
●
●
●●
●
●●●
●
●●
●●●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●●
●
●●
●
●
●
●
●
●
●●●
●
●●
●
●●●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●●
●
●●●
●
●●
●●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●●●
●
●●
●●●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●●
●
●●●
●
●●
●●
●●●
●
●●●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●●
●
●●
●
●
●●
●
●●●●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●●●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●●●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●●●●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●●●●
●
●●
●
●
●
●
●●
●
●
●●
●
●●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●●●
●
●
●
●
●
●
●
●●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●●●●
●
●
●
●
●
●
●●●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●●
●
●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●●
●
●●
●
●●●●
●
●
●
●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●●
●
●●●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●●
●
●●
●
●
●
●
●
●
●
●●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●●●●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●●
●
●●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●●
●
●
●●
●
●●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●●●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●●
●
●●●
●
●
●
●
●●
●
●
●
●●●
●
●
●●●
●●
●●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●●●
●
●
●
●●
●
●
●
●
●
●●
●
●●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●
●
●●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●●
●●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●●
●
●
●●
●●
●●
●●
●
●●●●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●
●
●
●
●
●
●●●●
●
●●
●
●●
●●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●●
●●●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●●
●
●●
●●
●
●●
●
●●
●●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●
●
●
●
●●●
●
●●
●
●●
●●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●●●
●
●●●
●
●
●
●
●●
●
●
●●●
●
●●●
●●
●●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
un2−
1un
2−2
R48
−2
R36
−2
R24
−2
R18
−2
R12
−2
R8−
2R
6−2
R4−
2R
2−2
R1−
2un
1−1
un1−
2R
48−
1R
36−
1R
24−
1R
18−
1R
12−
1R
8−1
R6−
1R
4−1
R2−
1R
1−1
R.5
−1
D48
−1
D36
−1
D24
−1
D18
−1
D12
−1
D8−
1D
6−1
D4−
1D
2−1
D1−
1D
.5−
1R
.5−
2D
48−
2D
36−
2D
24−
2D
18−
2D
12−
2D
8−2
D6−
2D
4−2
D2−
2D
1−2
D.5
−2
2.8
3.0
3.2
3.4
3.6
3.8
Log 2
inte
nsity
Array (Treatment)
BeadChip
1234
Elliot Kleiman (SDSU) Microarray Analysis Sept. 17, 2009 41 / 41